Restructuring results in 50% reduction in operating costs

Tuesday, 13 August 2019

Regeneus Ltd (ASX: RGS) announces it has completed a restructuring of its operations and implemented a number of cost saving initiatives that will deliver a 50 per cent reduction in recurring operating costs to $250,000 per month.

The initiatives ensure the ongoing alignment of the Company's operations to its revised strategy of developing therapies for the global pain market, utilising its Progenza and Sygenus technologies, as well as providing an extended cash runway to complete a major licensing deal for OA in Japan.